EPHX2 and cardiac hypertrophy: Inhibition of sEH hydrolase activity by pharmacological antagonists or genetic deletion of sEH increases EET levels in blood, thereby alleviating the progression of angiotensin II-mediated hypertension, atherosclerosis and cardiac hypertrophy in experimental animal models24, 41, 42.